Investigator-sponsored research

Program Description

Our Investigator-Sponsored Trials (IST) program provides support for external clinical research that advances medical and/or scientific knowledge about our products and clinical candidates to enhance patient care. Our current IST portfolio includes programs investigating:

• Brentuximab vedotin in lymphoma
• Tucatinib in breast and other HER2-expressing tumors
• Enfortumab vedotin in urothelial carcinoma and other Nectin-4 expressing tumors

The objective of our IST program is to provide funding and/or study drug for clinical research that will:

• Address unmet medical needs with new scientific data
• Support pilot studies that explore the feasibility of new investigational treatments

To discuss your proposed research or for questions about our process, please contact your regional Medical Science Liaison (MSL) or email us at IST@seagen.com for help identifying the MSL in your region.

Process Outline

1. Letters of Intent (LOI) are accepted on an ongoing basis via our online portal. 
2. The regional MSL will present the proposal to the Investigator-Sponsored Trial Review Committee (ISTRC). If accepted, a full protocol and budget is requested within 90 days, which will be reviewed by the ISTRC.
3. Following ISTRC approval, start-up regulatory and contracting activities may begin.

For a detailed description of our program, processes, and applicant responsibilities, click Program Overview (PDF).

Application and Questions

To apply for an IST related to brentuximab vedotin or tucatinib, please visit our online portal.

To apply for an IST related to enfortumab vedotin research, please visit the Astellas Investigator-Sponsored Research portal. Enfortumab vedotin proposals are reviewed jointly by Seagen and Astellas.

Please email IST@seagen.com with questions about our IST program.